ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Both wild type and BCR-ABL T315I lead to CML pathogenesis via signal transduction, which is initiated by binding of phosphorylation motif of BCR-ABL with the adapter proteins, for example, SH2 domain-containing protein Grb235, consequently resulting in activation of the downstream signaling pathway.